biostudies-literatureUnknown84(2)Hack CCNovartis Germany GmbH<h4>Introduction</h4>Adjuvant treatment of patients with early-stage breast cancer (BC) should include an aromatase inhibitor (AI). Especially patients with a high recurrence risk might benefit from an upfront therapy with an AI for a minimum of five years. Nevertheless, not much is known about the patient selection for this population in clinical practice. Therefore, this study analyzed the prognosis and patient characteristics of postmenopausal patients selected for a five-year upfront letrozole therapy.<h4>Patients and methods</h4>From 2009 to 2011, 3529 patients were enrolled into the adjuvant phase IV PreFace clinical trial (NCT01908556). Postmenopausal hormone receptor-positive BC patients, for whom an upfront five-year therapy with letrozole (2.5 mg/day) was indicated, were eligibleGeburtshilfe und Frauenheilkunde185-195https://www.ebi.ac.uk/biostudies/studies/S-EPMC10853028biostudies-literatureLong-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.PMC10853028Sutterlin MWMarme FBohm SMuller VBayer CMThomssen CHuebner HFehm TNWolf CUhrig SHofmann NMLuck HJJackisch CTheuser AKKellner SBrucker SYKolberg HCBrucker CAlmstedt KDall PSchneeweiss AHanf VAktas BKummel SWallwiener DUleer CMaass NRuebner MRack BRody AFasching PAHack CCKalder MJuhasz-Boss IBelleville EJanni WHaberle LGass PSchmatloch SRauh CHein AGoossens CfalseLong-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.<h4>Introduction</h4>Adjuvant treatment of patients with early-stage breast cancer (BC) should include an aromatase inhibitor (AI). Especially patients with a high recurrence risk might benefit from an upfront therapy with an AI for a minimum of five years. Nevertheless, not much is known about the patient selection for this population in clinical practice. Therefore, this study analyzed the prognosis and patient characteristics of postmenopausal patients selected for a five-year upfront letrozole therapy.<h4>Patients and methods</h4>From 2009 to 2011, 3529 patients were enrolled into the adjuvant phase IV PreFace clinical trial (NCT01908556). Postmenopausal hormone receptor-positive BC patients, for whom an upfront five-year therapy with letrozole (2.5 mg/day) was indicated, were eligible2024-01-01T00:00:00Z2024 Feb2026-06-02T19:21:30.131Z2024-11-06T02:20:11.904ZS-EPMC108530283834404510.1055/a-2238-3153